title: Therapeutic strategies for aggressive lymphomas: the trials of the DSHNHL.
authors.affiliation: Dept. of Medicine, Saarland University Schooel of Medicine, Homburg/Saar, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Schmits
authors.forename: B
authors.initials: B
authors.lastname: Glass
authors.forename: L
authors.initials: L
authors.lastname: Trümper
authors.forename: M
authors.initials: M
authors.lastname: Pfreundschuh
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005858:Germany; D006801:Humans; D007167:Immunotherapy; D007391:International Cooperation; D008228:Lymphoma, Non-Hodgkin / Q000145:classification / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction; D012307:Risk Factors; D000069283:Rituximab; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone